News & Media

Press release
Marketing Authorization Application for Simeprevir to the EMA for the treatment of patients with genotype 1 and genotype 4 hepatitis C is now filed

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that Janssen-Cilag International NV (Janssen) today has submitted a Marketing Authorization Application...

Read more
Press release
New data from Simeprevir phase III studies Quest 1 and 2 in hepatitis C patients will be presented at EASL 23-28 April in Amsterdam

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435)...

Read more
Press release
Data from Simeprevir in hepatitis C patients will be presented at EASL during 24-28 April in Amsterdam

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435)...

Read more
Press release
Annual Report 2012

Medivir Annual Report 2012 is now available at the company’s website: www.medivir.com.   Annual Report 2012http://www.medivir.se/v4/images/pdf/2013/Medivir-ENG-web_0403.pdf    About MedivirMedivir is an...

Read more
Press release
Notice of Annual General Meeting of Medivir AB (publ)

The shareholders in Medivir AB are hereby summoned to the annual general meeting on Monday 6 May 2013 at 2.00 p.m....

Read more
Press release
New Drug Application has been filed with FDA for Simeprevir (TMC435) for combination treatment of adult patients with genotype 1 chronic hepatitis C

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced that a new drug application (NDA) has been filed with the U.S....

Read more
Press release
Nomination Committee proposes new Board of Directors ahead of 2013 AGM

Stockholm, Sweden — Medivir AB (OMX: MVIR) today published the proposal for the new Board of Directors submitted by the Nomination...

Read more
Press release
Medivir strengthens its R&D organization

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced that the company will divide its current R&D organization into two parts,...

Read more
Press release
Results from a phase IIa study evaluating Simeprevir and Sofosbuvir in prior null responder Hepatitis C patients have been presented at CROI

In an all-oral regimen of simeprevir and sofosbuvir 96.3 percent (26/27) and 92.9 percent (13/14) of patients in the 12-week arm...

Read more
Press release
First interim results from a phase IIa study evaluating an all-oral regimen of Simeprevir and Sofosbuvir in prior null responder Hepatitis C patients

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced first interim results from the cohort 1 of a Phase IIa study...

Read more
Press release
Regulatory Application has now been filed for Simeprevir (TMC435) in Japan for the treatment of genotype 1 hepatitis C patients

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced that its partner Janssen now has submitted a regulatory application to the...

Read more
Press release
Financial Statement, 1 January – 31 December 2012*

Full-year (January − December) Net turnover totalled SEK 555.0 million (SEK 698.6 m). The profit/loss after tax was SEK -219.1 million...

Read more